Indole CB1 Allosteric Modulators for Oral Bioavailability
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapeutics targeting the cannabinoid CB1 receptor lack adequate solubility, plasma stability, and oral bioavailability, limiting their effectiveness in treating conditions such as pain, PTSD, and neurodegenerative disorders, and there is a need for non-addictive alternatives to opioid analgesics.
Innovation Solution
Development of a novel class of positive allosteric modulators (PAMs) with indole functionality, exemplified by GAT1102, which exhibit improved solubility and oral bioavailability, acting as CB1 PAMs or CB2 agonists/inverse agonists, and are effective in treating conditions like glaucoma, pain, and neurodegenerative disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If orthosteric CB1 ligands are used to target the endogenous ligand-binding site, then receptor activation is achieved, but solubility and oral bioavailability are inadequate
Solution Approach 1:
The patent introduces allosteric modulators as intermediary compounds that bind to a distinct site on the CB1 receptor rather than the orthosteric binding site. These modulators indirectly influence receptor activation by altering the conformation or affinity of the orthosteric site, thereby achieving therapeutic effects while improving solubility and oral bioavailability characteristics compared to direct orthosteric ligands.
2Reliability
If conventional CB1 therapeutics are developed to treat pain and neurodegenerative disorders, then therapeutic efficacy is achieved, but plasma stability is insufficient
Solution Approach 1:
The patent employs parameter changes by modifying the chemical structure of CB1 ligands to create allosteric modulators with altered physicochemical properties. These structural modifications include changes in molecular weight, lipophilicity, and functional groups, which collectively improve plasma stability while maintaining or enhancing therapeutic efficacy at the CB1 receptor.
3Reliability
If CB1 PAMs are used to provide non-addictive alternative to opioid analgesics, then pain relief is achieved, but selectivity and control of downstream pathways need improvement
Solution Approach 1:
The patent applies segmentation by developing allosteric modulators that selectively target specific downstream pathways of the CB1 receptor. By binding to distinct allosteric sites, these modulators can selectively enhance or inhibit specific signaling cascades (e.g., Gi/o protein coupling, beta-gamma subunit pathways) while leaving other pathways unaffected, thereby achieving pain relief with improved selectivity and reduced off-target effects.
4Ease of manufacture
If novel indole-based PAMs are developed to improve solubility and bioavailability, then druggability is enhanced, but structural complexity increases
Solution Approach 1:
The patent employs composite material principles by combining the indole core structure with various substituent groups (e.g., aromatic rings, heterocycles, alkyl chains) to create composite molecular structures. These composite indole-based compounds integrate multiple functional moieties that collectively improve solubility, bioavailability, and druggability while the modular nature of the composite structure allows for systematic optimization without excessive complexity.
Data Source
AI summary
Heteroaromatic compounds are provided which are allosteric modulators of the cannabinoid receptors and which are useful for the treatment of glaucoma, pain, neuropathic pain, post-traumatic stress disorder (PTSD), and neurodegenerative diseases such as Huntington's disease, Alzheimer's disease, Parkinson's disease, multiple sclerosis, and other diseases where cannabinoid receptors are involved.